Welcome to our dedicated page for Covalon Technologies news (Ticker: CVALF), a resource for investors and traders seeking the latest updates and insights on Covalon Technologies stock.
Covalon Technologies Ltd. (CVALF) is described in its news releases as an advanced medical technologies and medical device company with expertise in advanced wound care, vascular access, and surgical consumables. The Covalon news flow often combines clinical, commercial, and financial updates, giving investors and healthcare professionals insight into how its technologies are being adopted and how the business is performing.
Recent announcements include detailed financial results, where the company has reported multiple years of revenue growth, profitability, and a debt-free balance sheet, as well as the declaration and payment of its first-ever special cash dividend. These financial updates are accompanied by commentary on revenue by product category and sales channel, including U.S. Vascular Access and Surgical Consumables, U.S. Advanced Wound Care, and International channels.
Covalon’s news also highlights clinical milestones and conference activity. The company has announced a peer-reviewed study in the Journal of the Association for Vascular Access evaluating its VALGuard ae Vascular Access Line Guard in pediatric central line care, with reported reductions in CLABSI rates. It regularly reports on participation in major professional meetings such as the Association for Vascular Access Annual Scientific Meeting, the Association of Pediatric Hematology/Oncology Nurses Conference, and the ANCC National Magnet & Pathway to Excellence Conference, where it showcases VALGuard ae, CovaClear ae, IV Clear ae, and SurgiClear ae dressings.
Investors following CVALF news can expect updates on quarterly and annual financial results, dividend decisions, board and executive changes, new clinical evidence, health economic findings, and Covalon’s presence at investor conferences such as the Planet MicroCap Showcase. This combination of financial, clinical, and market-facing news provides context on how the company positions its technologies and on the evolution of its business across its key sales channels.
Covalon Technologies Ltd. announced the voting results from its Fiscal 2020 Annual and Special Meeting of Shareholders held on June 30, 2021. Shareholders approved all items, including the election of the Board of Directors, the appointment of auditors, and the amended stock option plan. A total of 11,030,811 shares, representing 42.72% of the company's shares, were voted. Notably, Amir Boloor and Ron Smith received 99.965% shareholder approval. The results will be filed on SEDAR, and further details are available in the management information circular dated May 26, 2021.
Covalon Technologies Ltd. (CVALF) is set to release its Q2 Fiscal 2021 financial results on May 31, 2021, before market opening. A conference call will follow at 9:00 AM EST for discussion. Participants can join via toll-free numbers in North America or local Toronto lines. Financial statements will be available on SEDAR and Covalon's website. Covalon specializes in patent-protected medical products aimed at improving patient outcomes across advanced wound care, infection management, and surgical procedures.
Covalon Technologies Ltd. (CVALF) will announce its fiscal 2021 Q1 financial results on March 1, 2021, before market opening. A conference call is scheduled for the same day at 9:00 AM EST, allowing stakeholders to discuss these results. Interested parties can participate via local and toll-free numbers provided in the release. Financial statements will be available on SEDAR and the company’s website. Covalon specializes in medical products aimed at improving patient outcomes in advanced wound care, infection management, and surgical procedures.
Covalon Technologies Ltd. (CVALF) is set to release its Fiscal 2020 Third Quarter financial results on August 24, 2020, prior to market opening. A conference call will be conducted at 9:00am EST on the same day to discuss these results. Investors can access the call via local and toll-free numbers provided. The results and related materials will be available on SEDAR and Covalon's investor relations site.